Fresenius sells biotech business to Israel's Neopharm
This article was originally published in Scrip
Executive Summary
Fresenius of Germany has sold its biotech subsidiary to the Fuhrer family, owners of Israeli pharmaceutical company Neopharm. The transaction includes the trifunctional antibody Removab (catumaxomab) and ATG-Fresenius S, a polyclonal antibody product for immunosuppression.